Neon’s next steps

Neon Therapeutics Inc.’s $70 million B round gives the company enough fuel to run three neoantigen programs in parallel.

Partner Fund Management led the round, which closed on Jan. 5. Additional new investors Fidelity Management and Research Co., Wellington Management, Inbio Ventures and Nextech Invest also participated alongside existing investors Third Rock Ventures and Access Industries...